Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q3 2018 · 10-Q
Revenue$64.76M$64.76M+29.2% vs Q3 2017 Net Income-$11.69M-$11.69MN/M vs Q3 2017 EPS Diluted-$0.13-$0.13N/M vs Q3 2017 Gross Profit$45,807,000+31.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow$5,638,000+121.4% Free Cash Flowderived$4,285,000+113.9% Margins · derivedGross margin70.7%+1.0 pt vs Q3 2017
Operating margin-8.1%+3.7 pt vs Q3 2017
Net margin-18.1%+4.9 pt vs Q3 2017
ended Sep 30, 2018 · filed Oct 25, 2018 · 25 d after period end